CompletedPHASE1, PHASE2NCT01432600

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
Rachid Baz, M.D., M.D
H. Lee Moffitt Cancer and Research Institute
Intervention
Pomalidomide(drug)
Enrollment
80 target
Eligibility
18 years · All sexes
Timeline
20112016

Study locations (3)

Collaborators

Celgene

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01432600 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials